Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.
Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.
Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.
Akero Therapeutics announced the publication of results from its Phase 2a BALANCED trial of efruxifermin (EFX) in the treatment of non-alcoholic steatohepatitis (NASH), showing significant reductions in liver fat and improvement in fibrosis after just 16 weeks of treatment. In the study, 48% of EFX patients normalized liver fat levels versus 5% in the placebo group. EFX demonstrated improved metabolic markers and was generally well tolerated, with minimal serious adverse events reported. The trial results contribute to the development of potentially groundbreaking NASH therapies.
Akero Therapeutics (Nasdaq: AKRO) announced new analyses from its Phase 2a BALANCED study, which evaluates efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH). Presented at the American Diabetes Association's 81st Scientific Sessions, findings show EFX significantly improves glucose metabolism and insulin sensitivity in NASH patients with type 2 diabetes. Additionally, increased adiponectin levels correlate with better liver health. Akero's ongoing studies suggest EFX may uniquely address metabolic dysregulation in NASH, positioning it as a promising treatment option.
Akero Therapeutics (AKRO) announced significant findings from its Phase 2a BALANCED study of efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH). Presented at the 2021 International Liver Congress, analyses reveal that a liver fat reduction of ≥17 U/L, coupled with normalizing liver fat, enhances the predictive power for NASH resolution. Key results show 69% of patients on 28mg EFX achieved ≥50% liver fat reduction, and 53% normalized liver fat by week 12. The company’s ongoing Phase 2b trials further explore EFX's potential in advanced fibrosis patients.
Akero Therapeutics (Nasdaq: AKRO) will present results from its Phase 2a BALANCED study at the 2021 EASL Congress on June 26, showcasing efruxifermin (EFX) improvements in NASH patients with compensated cirrhosis. Additionally, two presentations will occur at the 81st ADA Meeting from June 25-29. Akero emphasizes EFX's potential to reverse liver injury, improve glycemic control, and enhance lipoprotein profiles. With ongoing Phase 2b trials, the company aims to address the unmet medical needs in NASH, particularly for patients with type 2 diabetes.
Akero Therapeutics (Nasdaq: AKRO), a biotech firm focused on cardio-metabolic therapies, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. (ET). The company is developing treatments for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Its lead candidate, EFX, is undergoing a Phase 2b clinical trial named HARMONY, targeting NASH patients with F2/F3 fibrosis. Akero is based in South San Francisco. For more details, visit www.akerotx.com.
Akero Therapeutics (Nasdaq: AKRO) reported its first-quarter financial results for 2021, revealing significant progress in its NASH treatment program. Notably, 58% of patients treated with efruxifermin (EFX) showed improvement in fibrosis after 16 weeks, compared to 0% in the placebo group. The company has initiated two Phase 2b trials for NASH this year and plans to present additional data at upcoming conferences. Financially, Akero holds $250 million in cash, projecting sufficient funds through Q3 2023. Operating expenses rose to $15.1 million from $12.4 million year-over-year.
Akero Therapeutics (Nasdaq: AKRO) has appointed Yuan Xu, Ph.D., as an independent director to its board. Dr. Xu brings significant biopharmaceutical experience, having previously served as CEO of Legend Biotech and held senior roles at Merck, Novartis, Gilead, and GlaxoSmithKline. Her expertise will be instrumental as Akero advances its lead candidate, efruxifermin, into late-stage development for non-alcoholic steatohepatitis (NASH), a condition currently without approved therapies. This strategic move aims to bolster the company’s efforts in delivering innovative treatments.
Akero Therapeutics (Nasdaq: AKRO) announced the randomization of the first patient in its Phase 2b clinical study of Efruxifermin (EFX) for patients with F2/F3 non-alcoholic steatohepatitis (NASH), also known as the HARMONY study. This milestone reflects the company's continued progress, with screening and enrollment ahead of schedule. The trial aims to evaluate fibrosis regression after 24 weeks of treatment. EFX offers a potential new treatment option for NASH, a disease lacking FDA-approved therapies, impacting millions.
Akero Therapeutics (Nasdaq: AKRO) reported promising results from its Phase 2a clinical trial of efruxifermin (EFX) in cirrhotic patients with non-alcoholic steatohepatitis (NASH). Key findings include:
- 33% of EFX patients improved fibrosis by one stage without worsening NASH.
- 25% achieved NASH resolution.
- 58% showed histological improvements.
EFX was generally well-tolerated, with mild side effects noted. The trial's findings suggest potential for EFX as a foundational treatment for cirrhotic NASH, paving the way for further studies.
Akero Therapeutics, Inc. (Nasdaq: AKRO) announced plans to discuss new efficacy and safety data from the expansion cohort of its Phase 2a clinical trial for efruxifermin (EFX), aimed at treating adults with cirrhotic non-alcoholic steatohepatitis (NASH). The update, including biopsy results, will be presented in a press release and a webcast on March 22, 2021, at 4:30 p.m. ET. Akero is focused on developing treatments for NASH, a condition without current approved therapies.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
